key: cord-0687497-vqxxah00 authors: Innocenti, Idanna; Tomasso, Annamaria; Benintende, Giulia; Autore, Francesco; Fresa, Alberto; Vuono, Florenzia; Stirparo, Luca; Galli, Eugenio; D’Arena, Giovanni; Sorà, Federica; Efremov, Dimitar; Laurenti, Luca title: Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid‐19 pandemics date: 2022-02-02 journal: Hematol Oncol DOI: 10.1002/hon.2966 sha: 5db44869d78c50d517fbc6e18b3c4099850f63e1 doc_id: 687497 cord_uid: vqxxah00 Secondary antibody deficiency (SAD) is a frequent manifestation of chronic lymphocytic leukemia (CLL) that increases the risk of infections. However, no formal guideline are available regarding the eligibility for prophylaxis or the delivery method, dosage, frequency of administration and duration of immunoglobulin replacement therapy (IgRT). The aim of this study was to assess the efficacy and safety of subcutaneous IgRT (SCIg) and its impact on quality of life (QoL) of CLL pts in the Covid‐19 era. Ten CLL pts with SAD were treated with subcutaneous IgRT (SCIg) at our institution between October 2019 and December 2020. Median age was 66 years and five patients had comorbidities. Seven patients were receiving therapy for CLL when treatment with SCIg was initiated. All pts received 10 g total dose hyaluronidase‐free SCIg independently from body weight. The IgG level and CD4/CD8, CD19 and CD16/56 lymphocytes subset were recorded at baseline and every 3 months. No patient experienced infectious events nor Covid‐19 mediated interstitial pneumonia while on SCIg therapy. All patients tolerated well the therapy and experienced an increase of IgG levels, which was then stable in time. We conclude that SCIg administration in CLL pts with SAD is efficacious and safe as infectious prophylaxis. This route of administration appears particularly advantageous in the Covid‐19 era, because of the self‐administration at home which results in improvement in the QoL and reduced treatment expenditures. Secondary antibody deficiency (SAD) is typical of hematological malignancies such as chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and lymphoma, and can occur spontaneously or as a consequence of their treatment, which usually aggravates the underlying immune deficiency. [1] [2] [3] SAD is characterized by a decrease of functional and/or total serum immunoglobulin (Ig) levels in all their subclasses. Overall infection susceptibility is wide and most frequently presents with respiratory tract infections, septicemia or urinary tract infections (UTI). 4, 5 Recent data indicated a possible association between hypogammaglobinaemia and SARS-COV2 infection, which needs further validation. 6 SAD and T cell defects are observed at frequencies ranging from 25% to 85% of CLL patients, depending on duration, stage of disease, treatment (chemo-immunotherapy or novel agents), patient's age and comorbidities. 3, 5, [7] [8] [9] [10] [11] The pathogenesis is multifactorial and involves dysregulation of both innate immunity-with defects of complement, neutrophils and phagocytes function-and adaptive immunity-with defects of cell-mediated immunity and antibody production. 12 Such immune impairment can potentially be explained by two mechanisms: on one side, the interaction of CD95L on CLL-B cells with CD95L on plasma cells exerts a direct inhibitory effect on the latter; on the other side regulatory abnormalities and dysfunctional dendritic cells indirectly decrease the activity of T helper cells while increasing the activity of T suppressor cells. 2, 4, 9, 10, 11, 13 SAD increases the patients' risk to develop infections, which result in overall higher morbidity and mortality and are the cause of death in 25%-50% of patients. 3 This is why antibiotics administration and early vaccinations are recommended risk-reduction strategies in the clinical management of those patients. Moreover, in the last decades many attempts have been made to reconstitute a proper immunological defense through administration of exogenous immunoglobulins. The indication for the use of immunoglobulins replacement therapy (IgRT) depends not only on immunoglobulin levels, but also on other factors. 14 Hypogammaglobulinemia is a complication commonly observed both in naïve and previously treated CLL patients and is primarily due to effects that the leukemia cells exert directly on normal B cells and plasma cells and indirectly on T helper cells. 11, 12 Chronic lymphocytic leukemia patients are at high-risk for in- 14, 15 Proven specific antibody-response failure, defined as failure to mount at least a two-fold rise in IgG antibody titer to pneumococcal polysaccharide and polypeptide antigen vaccines, is another possible indication. 16 Another pitfall in the current recommendations is the previous treatment with either chemo-immunotherapy or newly developed drugs (i.e., BTK inhibitors or anti-BCL2), which calls for clarity since the chemo-free regimens are quickly evolving and largely used. 16 Dealing with IgRT discontinuation, evidence suggests that patients who did not experience any infective episode over a period of 12 months or those who present with an adequate antibody specific response can suspend the treatment. 19 and fever, whose frequency decreases with prolonged therapy. 23 None of AEs has been observed in our patients, except for a patient with atopic dermatitis (grade 2) 18 resolved by steroidal therapy. Two formulations are available with different schedules and dosages. The one used in our center was a hyaluronidase-free SCIg, administered every 2 weeks at two injection sites. The total dose was 10 g at each administration, independently from body weight. This very concentrated SCIg formulations and the use of two injections sites may avoid the discomfort given by the injected volume. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. https://orcid.org/0000-0001-7290-260X Francesco Autore https://orcid.org/0000-0002-7868-7469 Giovanni D'Arena https://orcid.org/0000-0002-3807-7287 Federica Sorà https://orcid.org/0000-0002-9607-5298 Luca Laurenti https://orcid.org/0000-0002-8327-1396 The peer review history for this article is available at https://publons. com/publon/10.1002/hon.2966. Immunoglobulin G treatment of secondary immunodeficiencies in the era of novel therapies The expanding field of secondary antibody deficiency: causes, diagnosis, and management The immunodeficiency of chronic lymphocytic leukaemia Secondary immunodeficiency in lymphoproliferative malignancies Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies COVID-19 among fit patients with CLL treated with venetoclax-based combinations Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin? Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches Perturbation of the normal immune system in patients with CLL Immune dysfunction in patients with chronic lymphocytic leukemia and challenges during COVID-19 pandemic Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian Society of Hematology iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL Prophylactic immunoglobulin therapy in secondary immune deficiency-an expert opinion Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximabrelated secondary hypogammaglobulinemia: a single-center experience in 61 patients Bioavailability of IgG administered by the subcutaneous route Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia COVID-19 vaccination: evaluation of risk for protection failure in chronic lymphocytic leukemia patients Convalescent plasma for the treatment of severe COVID-19 infection in cancer patients Outcome of hospitalized patients with COVID-19 pneumonia treated with high-dose immunoglobulin therapy in a prospective case series